NCT02156544

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

A Dose-block Randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519.

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	CKD-519
DRUG	placebo

Timeline

• Start date: 2014-06-01
• Primary completion: 2014-10-01
• Completion: 2015-08-01
• First posted: 2014-06-05
• Last updated: 2015-09-11

Locations

1 site across 1 country: South Korea